These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2080693)

  • 1. Lens changes in matched normals and hyperlipidemic patients treated with simvastatin for 2 years.
    Lundh BL; Nilsson SE
    Acta Ophthalmol (Copenh); 1990 Dec; 68(6):658-60. PubMed ID: 2080693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No lens changes caused by simvastatin results from a prospective drug safety study.
    Schmidt J; Schmitt C; Hockwin O
    Lens Eye Toxic Res; 1990; 7(3-4):643-50. PubMed ID: 2100182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up.
    Behrens-Baumann W; Thiery J; Wieland E; Fieseler HG; Seidel D
    Arzneimittelforschung; 1992 Aug; 42(8):1023-4. PubMed ID: 1418074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lovastatin and the human lens; results of a two year study. The MSDRL Study Group.
    Chylack LT; Mantell G; Wolfe JK; Friend J; Rosner B
    Optom Vis Sci; 1993 Nov; 70(11):937-43. PubMed ID: 8302530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.
    Behrens-Baumann W; Morawietz A; Thiery J; Creutzfeldt C; Seidel D
    Lens Eye Toxic Res; 1989; 6(1-2):331-7. PubMed ID: 2488025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin.
    Laties AM; Shear CL; Lippa EA; Gould AL; Taylor HR; Hurley DP; Stephenson WP; Keates EU; Tupy-Visich MA; Chremos AN
    Am J Cardiol; 1991 Mar; 67(6):447-53. PubMed ID: 1998274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular drug safety and HMG-CoA-reductase inhibitors.
    Schmidt J; Schmitt C; Hockwin O; Paulus U; von Bergmann K
    Ophthalmic Res; 1994; 26(6):352-60. PubMed ID: 7715916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy profile of simvastatin.
    Boccuzzi SJ; Bocanegra TS; Walker JF; Shapiro DR; Keegan ME
    Am J Cardiol; 1991 Nov; 68(11):1127-31. PubMed ID: 1951069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
    Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G
    Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Absence of cataractogenic effect of lovastatin (Mevinacor) so far].
    Ulbig M; Schneider T
    Fortschr Ophthalmol; 1991; 88(5):431-3. PubMed ID: 1757025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
    Stein E; Kreisberg R; Miller V; Mantell G; Washington L; Shapiro DR
    Arch Intern Med; 1990 Feb; 150(2):341-5. PubMed ID: 2405804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombocytopenic purpura during therapy with simvastatin.
    Possamai G; Bovo P; Santonastaso M
    Haematologica; 1992; 77(4):357-8. PubMed ID: 1427446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
    Bach LA; Cooper ME; O'Brien RC; Jerums G
    J Am Geriatr Soc; 1990 Jan; 38(1):10-4. PubMed ID: 2404052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.
    Harris ML; Bron AJ; Brown NA; Keech AC; Wallendszus KR; Armitage JM; MacMahon S; Snibson G; Collins R
    Br J Ophthalmol; 1995 Nov; 79(11):996-1002. PubMed ID: 8534671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lens opacity in patients with hypercholesterolemia and ischaemic heart disease. Electronic lens opacity measurements.
    Leino M; Pyörälä K; Lehto S; Rantala A
    Doc Ophthalmol; 1992; 80(4):309-15. PubMed ID: 1473445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
    Farmer JA; Washington LC; Jones PH; Shapiro DR; Gotto AM; Mantell G
    Clin Ther; 1992; 14(5):708-17. PubMed ID: 1468089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical tolerance of lovastatin and simvastatin.
    Bilheimer DW
    Cardiology; 1990; 77 Suppl 4():58-65. PubMed ID: 2073673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
    Schmidt J; Schmitt C; Hockwin O
    Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3 year simvastatin treatment and lens nuclear back scattering.
    Qian W; Söderberg PG; Chen E; Magnius K; Philipson B
    Br J Ophthalmol; 2000 May; 84(5):512-6. PubMed ID: 10781516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients.
    Lansberg PJ; Mitchel YB; Shapiro D; Kastelein JJ; Altman R; Jerums G; Bolzano K; Giannini S; Davignon J; DeWailly P
    Atherosclerosis; 1995 Aug; 116(2):153-62. PubMed ID: 7575771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.